

Bibliography

- El Sayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Care in Diabetes – 2023. Diabetes Care.* 2023;46(Supplement_1):S140-S157.
- Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. *Endocrine Practice.* 2023;29:305-340.
- Lalau JD, Kajbaf F, Bennis Youssef, et al. Metformin Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. *Diabetes care.* 2018;41:547-553.
- Newman, T. V., Munshi, K., Neilson, L., Good, C., Swart, E., Huang, Y., Henderson, R., & Parekh, N. (2021). Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study. *Managed Care Specialty Pharmacy*, 27(4), 435–443.
- Poonawalla, I. B., Bowe, A. T., Tindal, M. C., Meah, Y. A., & Schwab, P. (2021). A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2i versus GLP-1 agonists. *Diabetes Research and Clinical Practice*, 175, 108800. <https://doi.org/10.1016/j.diabres.2021.108800>
- Wilke, T., Picker, N., Muller, S., Sturmlinger, A., Deiters, B., Dittmar, A., Aberle, J., & Gabler, M. (2022). Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds. *Clinical Economics and Outcomes Research*, 14, 319–332. Dovepress. <https://doi.org/10.2147/CEOR.S357540>
- Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., & Laiterapong, N. (2022). First-Line Therapy for Type 2 Diabetes with Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. *Annals of Internal Medicine*, 175(10), 1392–1400. <https://doi.org/10.7326/m21-2941>
- Morton, J. I., Marquina, C., Shaw, J. E., Liew, D., Polkinghorne, K. R., Ademi, Z., & Magliano, D. J. (2022). Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. *Diabetologia*, 66. <https://doi.org/10.1007/s00125-022-05832-0>
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Das, S. R., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Kosiborod, M., Leon, J., Lyons, S. K., ... Gabbay, R. A. (2022). Introduction and methodology: *standards of care in diabetes—2023. Diabetes Care*, 46(Supplement_1). <https://doi.org/10.2337/dc23-sint>
- Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesenmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atiso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., Conget, I., ... REWIND Investigators (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet (London, England)*, 394(10193), 121–130. [https://doi.org/10.1016/S0140-6736\(19\)31149-3](https://doi.org/10.1016/S0140-6736(19)31149-3)
- Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). SEMAGLUTIDE and cardiovascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*, 375(19), 1834–1844. <https://doi.org/10.1056/nejmoa1607141>
- Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*, 375(4), 311–322. <https://doi.org/10.1056/nejmoa1603827>
- McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., ... Langkilde, A.-M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. *New England Journal of Medicine*, 381(21), 1995–2008. <https://doi.org/10.1056/nejmoa1911303>
- Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. *New England Journal of Medicine*, 377(7), 644–657. <https://doi.org/10.1056/nejmoa1611925>
- Patorno, E., Goldfine, A. B., Schneeweiss, S., Everett, B. M., Glynn, R. J., Liu, J., & Kim, S. C. (2018). Cardiovascular outcomes associated with Canagliflozin versus other non-gliflozin antidiabetic drugs: Population based cohort study. *BMJ*. <https://doi.org/10.1136/bmj.k119>
- Perkovic, V., Jardine, M. J., Neal, B., Bompaint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., ... Mahaffey, K. W. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *New England Journal of Medicine*, 380(24), 2295–2306. <https://doi.org/10.1056/nejmoa1811744>
- Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Ruff, C. T., Gause-Nilsson, I. A. M., Fredriksson, M., Johansson, P. A., Langkilde, A.-M., & Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*, 380(4), 347–357. <https://doi.org/10.1056/nejmoa1812389>

- Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England Journal of Medicine*, 373(22), 2117–2128. <https://doi.org/10.1056/nejmoa1504720>
- American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2023. *Diabetes Care*. 2023;46(Supplement 1):S140-S157.
- American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes – 2021. *Diabetes Care*. 2021;44(Supplement 1):S151-S167.
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney International*. 2022;102(5S):S1-S127.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017;377:644-57.
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med*. 2019;380:2295-306.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2019;380:347-57.
- Heerspink HJ, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2020;383:1436-46.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015;373:2117-28.
- US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease. Boehringer Ingelheim. March 12, 2020. Accessed November 9, 2021. Available at: <https://www.boehringer-ingelheim.us/press-release/us-fda-grants-fast-track-designation-jardiance-treatment-chronic-kidney-disease>.
- Herrington WG, Staplin N, Wanner JB, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2023;388:117-27.
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med*. 2020;383:2219-29.
- Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl J Med*. 2021;385:2252-63.
- de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care*. 2022;45:3075-90.